Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 20, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Transaction Type | Price per ADS | Volume (ADSs) |
|---|---|---|---|---|
| January 19, 2017 | American Depositary Shares (ADSs) | Acquisition (Dividend Re-investment) | $38.9854 | 1,323.343 (Total) |
Note: The total volume is the sum of individual transactions listed below.
Material Changes and Transaction Details
The filing details four separate acquisitions of ADSs on January 19, 2017, executed on the New York Stock Exchange (XNYS). All transactions were acquisitions resulting from the re-investment of dividends paid to shareholders on January 12, 2017.
- Dr. M M Slaoui (Chairman, Global Vaccines): Acquired 11.660 ADSs.
- Mr. B McNamara (CEO, Consumer Healthcare): Acquired 9.002 ADSs.
- Mr. D E Troy (SVP & General Counsel): Acquired 1,274.559 ADSs.
- Dr. K Slaoui (PCA of Dr. M M Slaoui): Acquired 28.122 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory notification of share transactions.
Investor Verification Checklist
- Verify the dividend payment date of January 12, 2017, to confirm the source of funds for these acquisitions.
- Confirm the total number of ADSs held by each executive post-transaction by reviewing their most recent beneficial ownership reports.
- Check the market price of GSK ADSs on January 19, 2017, to validate the reported transaction price of $38.9854.
- Review the company's annual report (Form 20-F) for broader financial performance metrics not included in this filing.